Sanofi’s alirocumab improves cardiovascular event rate over statinsAlirocumab, Sanofi’ s/Regeneron’s PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy … more ➔
Medimmune finds target against systemic sclerosisResearchers at Medimmune, AstraZeneca’s biologics arm, have identified a mechanism that drives the autoimmune disease systemic sclerosis. more ➔
Bioprocessing challenges in the focusAbout 300 bioeconomy experts from science and business came together in Strasbourg for the first edition of BIOKET to discuss up-scaling challenges, new processing technologies as well as the potential … more ➔
Sanofi to outsource antiinfectives R&D to EvotecEvotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofi’s antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agree … more ➔
Heidelberg Pharma inks US$334m R&D contract with Magenta TherapeuticsUnder an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes … more ➔
Investors keen to put money into AMR SMEsInvestments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus … more ➔
Santhera’s idebenone not efficient in PPMS patientsSwiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval … more ➔
Inhaled IL-4 halts neuron destruction in MS models An US-German team has found a way to halt the inflammatory brain cell destruction in mice with multiple sclerosis (MS) without suppression of the human immune system. more ➔
Convert Pharmaceuticals SA closes €13.6m Series A round Liège-based Convert Pharmaceuticals SA has been granted a total of €13.6m in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure, with non-dilutive … more ➔
Novo Holdings launches €135m fund to combat antimicrobial resistanceNovo Holdings has launched the REPAIR impact fund commissioned by the Novo Nordisk Foundation. The goal is to invest into early-stage drug developers with new concepts to fight antimicrobial … more ➔
